NSE ScannerPharmaceuticals · Pharmaceuticals: Generic · NSE: ZIMLAB · data 2026-10-31
Zim Laboratories Ltd.
In plain words
Price: 14.7% below its 52-week high of ₹159.81.
Delivery: 46.0% of traded shares were kept for delivery over the last 10 sessions, against 52.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹397 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | -2.2% |
| Profit growth, 3 years (yearly) | -37.9% |
At a glance
Promoters 30.3% (-3.0 pts in a year), pledged 0.0%, institutions 1.4%.
P/E 165.2, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 2.1%, ROCE 1.7%, operating margin 1.9%: how much profit it earns on the money it uses.
Debt/equity 0.43, Profit growth -37.9% and sales growth -2.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (2.1%).
- Thin operating margin (1.9%).
- Profit fell 37.9% a year over 3 years.
- Promoters cut their holding by 3.0 points in a year.
- Expensive on earnings (P/E 165.2).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
8/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 3/30: Delivery 37.9% over the last 20 sessions vs 52.1% in the 40 before (0.73x); shares delivered per day 1.06x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 30.30% | 30.36% | 30.35% | 33.26% |
| Foreign institutions (FII) | 0.17% | 0.03% | — | 0.02% |
| Domestic institutions (DII) | 1.19% | 1.33% | 0.07% | 0.20% |
| Mutual funds | 1.18% | 1.07% | — | — |
| Retail investors | 13.45% | 14.42% | 16.67% | 18.65% |
| Number of shareholders | 13,057 | 14,510 | 16,636 | 17,251 |
Common questions
How much do promoters hold in Zim Laboratories Ltd.?
Promoters held 30.30% of Zim Laboratories Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Zim Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.43.
What is Zim Laboratories Ltd.'s P/E ratio?
About 165.2, based on the last 12 months' earnings and a price of ₹136.29 (data 2026-10-31).
What is the 52-week high and low of Zim Laboratories Ltd.?
The 52-week high is ₹159.81 and the 52-week low is ₹59.31.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Zim Laboratories Ltd. | ₹136.29 | ₹732 cr | 165.2 | — | 2.1% | 1.7% | 0.43 | +72.5% |
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
| Kilitch Drugs (India) Limited | ₹201.32 | ₹703 cr | 23 | — | 12.5% | 12.3% | 0.32 | +1.5% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
| Hexagon Nutrition Limited | ₹54.11 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.1% |
| Wanbury Limited | ₹189.21 | ₹664 cr | 11.6 | — | 64.9% | 31.1% | 1.57 | -25.8% |
Compare ZIMLAB with SGRL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZIMLAB in NSE Scanner →